Effect of ALlopurinol in Addition to Hypothermia for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a Blinded Randomized Placebo-controlled Parallel Group Multicenter Trial for Superiority (Phase III)

Who is this study for? Patients with hypoxic-ischemic brain injury
What treatments are being studied? Allopurinol
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of death or long-term disability in infants born at term in the western world, affecting about 1-4 per 1.000 life births and consequently about 5-20.000 infants per year in Europe. Hypothermic treatment became the only established therapy to improve outcome after perinatal hypoxic-ischemic insults. Despite hypothermia and neonatal intensive care, 45-50% of affected children die or suffer from long-term neurodevelopmental impairment. Additional neuroprotective interventions, beside hypothermia, are warranted to further improve their outcome. Allopurinol is a xanthine oxidase inhibitor and reduces the production of oxygen radicals and brain damage in experimental, animal, and early human studies of ischemia and reperfusion. This project aims to evaluate the efficacy and safety of allopurinol administered immediately after birth to near-term infants with HIE in addition to hypothermic treatment.

Eligibility
Participation Requirements
Sex: All
Maximum Age: Newborn
Healthy Volunteers: f
View:

⁃ Term and near-term infants with a history of disturbed labour who meet at least one criterion of perinatal acidosis (or ongoing resuscitation) and at least two early clinical signs of potentially evolving encephalopathy as defined herein:

⁃ Severe perinatal metabolic acidosis or ongoing cardiopulmonary resuscitation at 5 min after birth:

⁃ At least 1 out of the following 5 criteria must be met

• Umbilical (or arterial or reliable venous) blood gas within 30 min after birth with pH\<7.0

• Umbilical (or arterial or reliable venous) blood gas within 30 min after birth with base deficit ≥16 mmol/l

• Need for ongoing cardiac massage at/beyond 5 min postnatally

• Need for adrenalin administration during resuscitation

• APGAR score ≤5 at 10min AND

⁃ Early clinical signs of potentially evolving encephalopathy:

⁃ At least 2 out of the following 4 criteria must be met:

• Altered state of consciousness (reduced or absent response to stimulation or hyperexcitability)

• Severe muscular hypotonia or hypertonia,

• Absent or insufficient spontaneous respiration (e.g., gasping only) with need for respiratory support at 10 min postnatally

• Abnormal primitive reflexes (absent suck or gag or corneal or Moro reflex) or abnormal movements (e.g., potential clinical correlates of seizure activity)

Locations
Other Locations
Austria
Medizinische Universitaet Wien
RECRUITING
Vienna
Belgium
Katholieke Universiteit Leuven
RECRUITING
Leuven
Estonia
Tartu Ulikool
RECRUITING
Tartu
Finland
Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä
RECRUITING
Helsinki
Germany
University Hospital Tübingen
RECRUITING
Tübingen
Italy
Universita Degli Studi Di Udine
RECRUITING
Udine
Netherlands
Universitair Medisch Centrum Utrecht
RECRUITING
Utrecht
Norway
Oslo Universitetssykehus Hf
RECRUITING
Oslo
Poland
Uniwersytet Medyczny Im Karola Marcinkowskiego W Poznaniu
WITHDRAWN
Poznan
Portugal
Universidade Do Porto
WITHDRAWN
Porto
Spain
Para La Investigacion Del Hospital UniversitarioLa Fe De La Comunidad Valenciana
RECRUITING
Valencia
Switzerland
Universitaet Zuerich
RECRUITING
Zurich
Contact Information
Primary
Oldershausen Gabriele
Albino@med.uni-tuebingen.de
+49 7071 29-86176
Time Frame
Start Date: 2018-03-25
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 760
Treatments
Active_comparator: Allopurinol
Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
Placebo_comparator: Placebo
mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
Related Therapeutic Areas
Sponsors
Leads: University Hospital Tuebingen
Collaborators: Fundación para la Investigación del Hospital Clínico de Valencia, Poznan University of Medical Sciences, Tartu University Hospital, Universidade do Porto, University of Helsinki, University of Zurich, UMC Utrecht, University of Vienna, Technische Universität Dresden, Helsingin Ja Uudenmaan Sairaanhoitopiirin, Università degli Studi di Udine, Oslo University Hospital, ACE Pharmaceuticals BV, KU Leuven

This content was sourced from clinicaltrials.gov